A Phase 2/3 interventional study of YM150 and enoxaparin in Venous Thromboembolism and Arthroplasty, Replacement, Hip, sponsored by Astellas Pharma Europe B.V.. Completed at 156 sites in 28 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-10-27.
Sponsored by Astellas Pharma Europe B.V. (part of Astellas Pharma Inc) · Phase 2/3, Interventional, and Prevention
The purpose of this study is to evaluate the efficacy and safety of various doses of YM150 (the experimental drug) compared to enoxaparin in the prevention of venous thromboembolism in patients that are undergoing elective hip replacement surgery.
708 studies on the registry are indexed under Venous Thromboembolism; 152 are open to participants now.
This study's enrollment of 1,992 is above the median of 257 across 390 interventional studies indexed under Venous Thromboembolism.
Browse Venous Thromboembolism studies →Astellas Pharma Europe B.V. is the lead sponsor of 94 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: YM150
Drug: YM150
Drug: YM150
Drug: YM150
Drug: enoxaparin
oral
SC injection
Incidence of symptomatic Venous Thromboembolisms and death from all causes
Time frame: 12 days
Incidence of all Venous Thromboembolic events
Time frame: Until day 12, during the treatment period, follow-up period and entire study period
Incidence of Bleeding events
Time frame: During the treatment period, follow-up period and entire study period
Showing the first 100 of 156 sites across 28 countries.
The record gives a start of Apr 2009, a primary completion of Jun 2010 and a completion of Aug 2010. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Darexaban